Study Of Investigational Drug To Treat Cocaine And Methamphetamine Addiction

Armen Hareyan's picture

Catalyst Pharmaceutical Partners announced positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis.

These data potentially provide a basis for linking CPP-109 to the extensive body of published pre-clinical and clinical literature on Sabril.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.


I would like to know if this is open to public studies. i know people who need these type of pills and was wondering if we could get them?